Launches of Tuzulby® methylphenidate prolonged-release chewable tablets and Paxneury® guanfacine prolonged-release tablets, also in 5mg, 6mg, and 7mg strengthsTwo differentiated treatments exemplify ...

Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental condition that causes hyperactivity and impulsivity in children and adults. If left untreated ...

Adults can have ADHD, often undiagnosed since childhood. Dr. Dania Antalaya explains symptoms, how adult diagnosis works, and ...

German CNS-focused specialist Neuraxpharm Group announced the launches in Europe of Tuzulby (methylphenidate hydrochloride) prolonged-release chewable tablets and Paxneury (guanfacine) ...

Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that China's National Medical Products Administration (NMPA) has approved the New Drug Application for Serdexmethylphenidate ...

ADHD is a neurodevelopmental condition that affects both children and adults. It is characterised by symptoms such as ...

Angela Myers is a freelance writer covering mental health, wellness and nutrition. She’s also conducted award-winning research on how to better communicate about sexual violence prevention and mental ...

The first medical device to treat childhood attention deficit hyperactivity disorder, or ADHD, was OK'd Friday by the US Food and Drug Administration. Designated for children ages 7 to 12 who are not ...

Mentavi Health is a telehealth platform providing mental health services. Its ADHD Online (ADO) division focuses on patients with attention-deficit/hyperactivity ...

Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that China's National Medical Products Administration ...

Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that China's National Medical Products Administration ...